Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 33Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 11Triple Negative Breast Neoplasms 3Recurrence 3Esophageal Squamous Cell Carcinoma 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Unspecified Adult Solid Tumor, Protocol Specific 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Primary Breast Cancer 1Pathologic Residual Cancer Cells 1Ovarian Neoplasms 1Osteosarcoma 1Nonhematologic Malignancies 1Non-small Cell Lung Cancer Stage â…¡ 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplasms, Connective and Soft Tissue 1Neoplasm Metastasis 1NSCLC 1

Interventions

pyrotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2 Positive Breast Cancer × Vinorelbine × Clear all
NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡